PublisherDOIYearVolumeIssuePageTitleAuthor(s)Link
Clinical and Molecular Hepatology10.3350/cmh.2022.00472022283575-579Clinical significance of the discrepancy between radiological findings and biochemical responses in atezolizumab plus bevacizumab for hepatocellular carcinomaHideki Iwamoto, Shigeo Shimose, Takashi Niizeki, Hironori Koga, Takuji Torimura, http://e-cmh.org/upload/pdf/cmh-2022-0047.pdf, http://e-cmh.org/journal/view.php?doi=10.3350/cmh.2022.0047, http://e-cmh.org/upload/pdf/cmh-2022-0047.pdf
Cancers10.3390/cancers13215475202113215475Changing the Treatment Paradigm for Hepatocellular Carcinoma Using Atezolizumab plus Bevacizumab Combination TherapyMasatoshi Kudohttps://www.mdpi.com/2072-6694/13/21/5475/pdf
10.21203/rs.3.rs-2564957/v12023Cost-effectiveness analysis of sorafenib, lenvatinib, atezolizumab plus bevacizumab and sintilimab plus bevacizumab for the treatment of advanced hepatocellular carcinoma in ChinaHongyu Gong, Siew Chin ONG, Fan Li, Keying Zhao, Zhiying Weng, Zhengyou Jianghttps://www.researchsquare.com/article/rs-2564957/v1, https://www.researchsquare.com/article/rs-2564957/v1.html
10.21203/rs.3.rs-1722962/v12022Perfusion Change of Hepatocellular Carcinoma during Atezolizumab plus Bevacizumab Treatment: A Pilot StudyEzinwanne Onuoha, Andrew D. Smith, Robert Cannon, Mohd Khushman, Harrison Kimhttps://www.researchsquare.com/article/rs-1722962/v1, https://www.researchsquare.com/article/rs-1722962/v1.html
Journal of Clinical and Experimental Hepatology10.1016/j.jceh.2022.07.00320221261575-1576Updated Efficacy and Safety Data from IMbrave150: Atezolizumab Plus Bevacizumab vs. Sorafenib for Unresectable Hepatocellular CarcinomaAkash Royhttps://api.elsevier.com/content/article/PII:S0973688322001682?httpAccept=text/xml, https://api.elsevier.com/content/article/PII:S0973688322001682?httpAccept=text/plain
The Lancet Oncology10.1016/s1470-2045(20)30476-92020219e413Atezolizumab plus bevacizumab for unresectable hepatocellular carcinoma – Authors' replysKyung-Hun Lee, Michael S Leehttps://api.elsevier.com/content/article/PII:S1470204520304769?httpAccept=text/xml, https://api.elsevier.com/content/article/PII:S1470204520304769?httpAccept=text/plain
Liver Cancer10.1159/000514312202110285-93Sequential Therapy for Hepatocellular Carcinoma after Failure of Atezolizumab plus Bevacizumab Combination TherapyMasatoshi Kudohttps://www.karger.com/Article/Pdf/514312, https://www.karger.com/Article/Pdf/514312
Liver Cancer10.1159/000505189202092119-137A New Era in Systemic Therapy for Hepatocellular Carcinoma: Atezolizumab plus Bevacizumab Combination TherapyMasatoshi Kudohttps://www.karger.com/Article/Pdf/505189, https://www.karger.com/Article/Pdf/505189
Medicinus10.19166/med.v10i2.7023202310277A Comparative Efficacy of Atezolizumab plus Bevacizumab Versus Sorafenib in Advanced Hepatocellular Carcinoma: A ReviewKristin Talia Marbun, Juandy Johttps://ojs.uph.edu/index.php/MED/article/viewFile/7023/3235, https://ojs.uph.edu/index.php/MED/article/viewFile/7023/3235
The Lancet Oncology10.1016/s1470-2045(20)30430-72020219e412Atezolizumab plus bevacizumab for unresectable hepatocellular carcinomaXu Yang†, Dongxu Wang†, Jianzhen Lin, Xiaobo Yang, Haitao Zhaohttps://api.elsevier.com/content/article/PII:S1470204520304307?httpAccept=text/xml, https://api.elsevier.com/content/article/PII:S1470204520304307?httpAccept=text/plain